We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

190 hedge funds and large institutions have $1.91B invested in Myriad Genetics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

24,360% more call options, than puts

Call options by funds: $17.1M | Put options by funds: $70K

69% more capital invested

Capital invested by funds: $1.13B → $1.91B (+$778M)

1.75% more ownership

Funds ownership: 99.52% → 101.27% (+1.8%)

4% less funds holding

Funds holding: 197 → 190 (-7)

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

Holders
190
Holders Change
-7
Holders Change %
-3.55%
% of All Funds
3.03%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
61
Reduced
75
Closed
28
Calls
$17.1M
Puts
$70K
Net Calls
+$17.1M
Net Calls Change
+$15.8M

Top Buyers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$32.3M
2
GCM
Glenview Capital Management
New York
+$22.3M
3
Bank of America
Bank of America
North Carolina
+$15.9M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$11.6M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.79M

Top Sellers

1
State Street
State Street
Massachusetts
-$8.48M
2
Invesco
Invesco
Georgia
-$7.81M
3
Morgan Stanley
Morgan Stanley
New York
-$5.51M
4
EARNEST Partners
EARNEST Partners
Georgia
-$4.95M
5
BlackRock
BlackRock
New York
-$4.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
26
Allianz Asset Management
Germany
$8.13M +$365K +17,983 +5%
Mirae Asset Global Investments
27
Mirae Asset Global Investments
South Korea
$7.79M +$204K +10,064 +3%
Ameriprise
28
Ameriprise
Minnesota
$7.22M -$157K -7,749 -2%
Wells Fargo
29
Wells Fargo
California
$7.12M +$1.29M +63,568 +26%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$6.25M +$229K +11,282 +4%
Legal & General Group
31
Legal & General Group
United Kingdom
$5.51M -$123K -6,039 -2%
N
32
Nuveen
North Carolina
$5.12M -$591K -29,087 -12%
Fisher Asset Management
33
Fisher Asset Management
Washington
$4.27M -$129K -6,359 -3%
ACM
34
Altium Capital Management
New York
$4.18M -$650K -32,000 -15%
Nordea Investment Management
35
Nordea Investment Management
Sweden
$4.18M -$56.2K -2,768 -2%
Citigroup
36
Citigroup
New York
$4.07M +$668K +32,890 +23%
Swiss National Bank
37
Swiss National Bank
Switzerland
$4.06M -$402K -19,800 -10%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$3.95M -$741K -36,492 -18%
PAMP
39
Polar Asset Management Partners
Ontario, Canada
$3.86M -$2.16M -106,300 -39%
JP Morgan Chase
40
JP Morgan Chase
New York
$3.67M +$349K +17,176 +12%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$3.65M +$2.79M +137,442 +693%
CS
42
Credit Suisse
Switzerland
$3.46M -$650K -31,981 -18%
Public Sector Pension Investment Board (PSP Investments)
43
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$3.31M -$107K -5,285 -4%
Macquarie Group
44
Macquarie Group
Australia
$3.14M – – –
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$2.94M -$791K -38,933 -23%
State of New Jersey Common Pension Fund D
46
State of New Jersey Common Pension Fund D
New Jersey
$2.78M – – –
Envestnet Asset Management
47
Envestnet Asset Management
Illinois
$2.72M -$543K -26,721 -19%
Assenagon Asset Management
48
Assenagon Asset Management
Luxembourg
$2.58M +$385K +18,948 +21%
Natixis Advisors
49
Natixis Advisors
Massachusetts
$2.53M +$1.03M +50,773 +87%
AllianceBernstein
50
AllianceBernstein
Tennessee
$2.52M -$243K -11,959 -10%
1
2
3 4 5

MYGN Hedge Fund Activity: Q1 2023 in Review

190 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2023, worth a combined $1.91B — up 69% from $1.13B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of MYGN and 23 opened new positions — a net loss of 5 holders — while 75 trimmed existing stakes and 61 added.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $32.3M. The largest seller was State Street, cutting an estimated $8.48M.

  • 190 institutional investors held Myriad Genetics (MYGN) as of Q1 2023, down from 197 in Q4 2022.
  • Funds reported $1.91B of Myriad Genetics stock for Q1 2023, up 69% quarter-over-quarter.
  • 23 funds opened new Myriad Genetics positions in Q1 2023 and 28 closed out, a net change of -5 holders.
  • The largest Myriad Genetics buyer in Q1 2023 was Balyasny Asset Management, an estimated $32.3M added.
  • The largest Myriad Genetics seller in Q1 2023 was State Street, an estimated $8.48M sold.

Based on aggregated 13F filings for Q1 2023.